Rush for diabetes and weight-loss drug Ozempic puts cross-border sales in spotlight
VANCOUVER — The Canadian Pharmacists Association says protecting Canadian drug supplies from mass exportation to the U.S. market remains a priority in light of British Columbia’s recent move to limit sales of the diabetes drug Ozempic, which has been hyped as a weight-loss treatment.
Joelle Walker, the association’s vice-president of public and professional affairs, says cross-border sales of Canadian drugs to Americans seeking lower prices has been a long-standing issue for the country’s health-care system.
Walker says the concern is not with small numbers of Americans coming over the border to buy cheaper drugs, but rather any large-scale quantities of drugs being exported and diverted from Canada’s limited supply .
In the case of Ozempic, which is approved to treat Type 2 diabetes, Walker says the internet and intense media coverage have fuelled demand for the drug for its weight-loss properties.